Journal of Kidney

Classical Renin angiotensin system in Kidney Physiology

Tejochandra Vanteddu^{* *}Correspondence: Tejochandra Vanteddu, Department of Pharmacology, Jawaharlal Nehru Technological University, Kakinada, India, Email:

Author info »

Renin Angiotensin

The renin-angiotensin framework (RAS) is one of the significant control frameworks for pulse and liquid equilibrium. The major naturally dynamic chemical created by this framework, angiotensin (Ang) II, is delivered by consecutive cleavage of peptides got from the substrate atom angiotensinogen (Agt). Ang II ties to explicit receptors, setting off a wide scope of organic activities affecting basically every framework on the body including the cerebrum, heart, kidney, vasculature, and resistant framework. Be that as it may, an essential capacity of the RAS is in circulatory homeostasis, securing body liquid volumes, and unusual initiation of the RAS can add to the advancement of hypertension, cardiovascular hypertrophy, and cardiovascular breakdown. In such manner, pharmacological inhibitors of the combination or movement of Ang II have demonstrated tremendously valuable in cardio-vascular therapeutics. For instance, angiotensins changing over catalyst (ACE) inhibitors are viable and broadly utilized for the treatment of hypertension, congestive cardiovascular breakdown, and kidney sicknesses.

Angiotensinogen

Angiotensinogen (Agt) is the lone known substrate of renin which divides a 10 amino corrosive peptide from its N-end, Angiotensin I, which is consequently separated by ACE to frame Angiotensin II, the major organically dynamic peptide produced by the RAS. Agt was first cloned in 1983 from rodent liver by Ohkubo et al. The human angiotensinogen (AGT) quality is situated on chromosome 1, while the mouse Agt quality is on chromosome 8. Agt homologues are available all through vertebrates and there is an ortholog in fish and the shark Callorhinchus Millie. While the C-terminal arrangements encoding Angiotensin I are saved across vertebrates, there is variable homology in different spaces of Agt, bringing about species explicitness to the Agt-renin response. For instance, human Agt can't be severed by mouse renin and the other way around

Symptomatology

Agt has a place with the superfamily of non-inhibitory Serpin A8 proteins, which are a huge and assorted superfamily of protease inhibitors and related proteins. The mark primary components of serpins comprise of three β sheets and 8 to 9 α helices. Zhou and partners as of late settled the construction of the Agt protein by x-beam crystallography. This report showed that the renin cleavage site which at last outcomes in the freedom of the decapeptide, Angiotensin I, covered inside the N-terminal tail of this huge protein. At the point when Agt is oxidized, there is a conformational change allowing access and cleavage by renin delivering Angiotensin I. In that capacity, renin has a fourfold higher reactant movement for Angiotensin I arrangement when Agt is oxidized contrasted with the decreased type of Agt.

Symptomatology

Agt has a place with the superfamily of non-inhibitory Serpin A8 proteins, which are a huge and assorted superfamily of protease inhibitors and related proteins. The mark primary components of serpins comprise of three β sheets and 8 to 9 α helices. Zhou and partners as of late settled the construction of the Agt protein by x-beam crystallography. This report showed that the renin cleavage site which at last outcomes in the freedom of the decapeptide, Angiotensin I, covered inside the N-terminal tail of this huge protein. At the point when Agt is oxidized, there is a conformational change allowing access and cleavage by renin delivering Angiotensin I. In that capacity, renin has a fourfold higher reactant movement for Angiotensin I arrangement when Agt is oxidized contrasted with the decreased type of Agt.

References

1. Wu C, Lu H, Cassis LA, Daugherty A. Molecular and pathophysiological features of angiotensinogen: A mini review. N Am J Med Sci. 2011; 4:183–190.
2. Zhou A, Carrell RW, Murphy MP, Wei Z, Yan Y, Stanley PL, et al. A redox switch in angiotensinogen modulates angiotensin release. Nature. 2010; 468:108–111.
3. Zhou X, Sigmund CD. Chorionic enhancer is dispensable for regulated expression of the human renin gene. Am J Physiol Regul Integr Comp Physiol. 2008;294:279–287.
4. Wong DW, Oudit GY, Reich H, Kassiri Z, Zhou J, Liu QC, Backx PH, Penninger JM, et al. Loss of angiotensin-converting enzyme-2 (Ace2) accelerates diabetic kidney injury. Am J Pathol. 2007; 171:438–451.
5. Kamiyama M, Zsombok A, Kobori H. Urinary angiotensinogen as a novel early biomarker of intra renal renin-angiotensin system activation in experimental type 1 diabetes. J Pharmacol Sci. 2012; 119:314–323.
6. Ito M, Oliverio MI, Mannon PJ, Best CF, Maeda N, Smithies O, et al. Regulation of blood pressure by the type 1A angiotensin II receptor gene. Proc Natl Acad Sci U S A. 1995; 92:3521–3525.